CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company
focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced that it has commenced
an underwritten public offering of $150 million of its common stock. Intellia also intends to grant the underwriters a 30-day
option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of
the shares in the proposed offering are to be sold by Intellia.
Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the proposed offering. The
offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
The shares are being offered by Intellia pursuant to a shelf registration statement that was previously filed with, and
subsequently declared effective by, the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating
to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus
relating to these securities may be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One
Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attn: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system.
Forward-Looking Statements
This press release contains "forward-looking statements" of Intellia within the meaning of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not limited to, those relating to Intellia’s expectations regarding
the completion, timing and size of the public offering, and its expectations with respect to granting the underwriters a 30-day
option to purchase additional shares. Any forward-looking statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and
uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, include, but are not
limited to, market conditions and the satisfaction of customary closing conditions related to the proposed public offering. For a
discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors in Intellia’s other filings with the SEC, including those
contained or incorporated by reference in the preliminary prospectus supplement related to the proposed public offering to be filed
with the SEC. All information in this press release is as of the date of the release, and Intellia undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
